Imidazo Pyrimidine Compounds for the Inhibition of Oncogenic KRAS Mutations in Cancer Therapy
- ACS Med Chem Lett. 2025 Oct 30;16(11):2194-2196. doi: 10.1021/acsmedchemlett.5c00628.
Affiliations
- 1. Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
PMID: 41256973
DOI: 10.1021/acsmedchemlett.5c00628
Abstract
This highlight outlines the development of novel imidazo-pyrimidine compounds as potent inhibitors targeting oncogenic KRAS mutations, including G12D, G12V, and G12C. The disclosure includes details on synthetic methods, biological evaluation, metabolic stability, and pharmaceutical compositions.
Products
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-